Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy

Journal of Neuro-Oncology

Volumn 63, Issue 1, 2003, Pages 87-95

  Watanabe, Takao ^a   Katayama, Yoichi ^a   Yoshino, Atsuo ^a   Komine, Chiaki ^a   Yokoyama, Takakazu ^a   Fukushima, Takao ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Dose escalation; Lymphoma; Methotrexate; Neurotoxicity; Radiation therapy

Indexed keywords

FOLINIC ACID; METHOTREXATE;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ARTICLE; BRAIN DISEASE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DELAYED NEUROTOXICITY; DEMENTIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; LONG TERM CARE; MALE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NEUTROPENIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; RADIATION DOSE; STEREORADIOGRAPHY; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, DIFFUSE; LYMPHOMA, LARGE-CELL; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS;

EID: 0038544575     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023760824739     Document Type: Article

References (40)

1. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, Guy G, Lapierre F: Primary intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg 92: 261-266, 2000
2. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, Bouabdallah R, Coiffier B, Wagner J-P, Le Mevel A, Dramais-Marcel D, Baumelou E, Chauvin F, Biron P: High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16: 864-871, 1998
3. Hayakawa T, Takakura K, Abe H, Yoshimoto T, Tanaka R, Sugita K, Kikuchi H, Uozumi T, Hori T, Fuki H, Ushio Y, Nomura K, Matsutani M, Mohri N, Kamanishi T, Aozasa K, Nagashima K: Primary central nervous system lymphoma in Japan: A retrospective co-operative study by CNS-Lymphoma Study Group in Japan. J Neuro-Oncol 9: 197-215, 1994
4. Jellinger KA, Paulus W: Primary central nervous system lymphomas: An update. J Cancer Res Clin Oncol 119: 7-27, 1992
5. DeAngelis LM: Current management of primary central nervous system lymphoma. Oncology 9: 63-78, 1995
6. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman DU, Thomson JW, Murray KJ: Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9-17, 1992
7. Nelson DF: Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neuro-Oncol 43: 241-247, 1999
8. Blay JY, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, Biron P: The CR5 protocol: A regimen of high-dose chemotherapy and radiotherapy in primary central nervous system lymphoma of patients with no known cause of immunosuppression. Blood 86: 2922-2929, 1995
9. Fine HA: Treatment of primary cerebral central nervous system lymphoma: Still more questions than answers. Blood 86: 1093-1104, 1995
10. Glass J, Gruber ML, Cher L, Hochberg FH: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 81: 188-195, 1994
11. Hiraga S, Arita N, Ohnishi T, Kohmura E, Yamamoto K, Oku Y, Taki T, Sato M, Aozasa K, Yoshimine T: Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91: 221-230, 1999
12. O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18: 519-526, 2000
13. Shapiro WR: High-dose methotrexate in malignant gliomas. Cancer Treat Rep 61: 753-756, 1977
14. Bacci G, Gherlinzoni F, Picci P, Van Horn JR, Jaffe N, Guerra A, Ruggieri P, Biagini R, Capanna R, Toni A: Adriamycin-methotrexate high dose versus adriamycin-methotrexate dose as adjuvant chemotherapy for osteosarcoma of the extremities: A randomized study. Eur J Cancer Clin Oncol 22: 1337-1347, 1986
15. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: Analysis of the literature. Cancer 78: 2127-2135, 1996
16. Winkler K, Berson G, Delling G, Heise U, Kabisch H, Purfurst C, Berger J, Ritter J, Jurgens H, Gerein V: Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 2: 617-624, 1984
17. Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289: 770-773, 1973
18. Tetet ML, Margolin KA, Doroshow JH, Akman S, Leong LA, Morgan RJ Jr, Raschoko JW, Slatkin N, Somlo G, Longmate JA, Carroll MI, Newman EM: Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46: 19-26,2000
19. Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, Fliessbach K, Deckert M, Van Roost D, Fimmers R, Bode U, Klockgether T: Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: A pilot study. J Neurol Neurosurg Psychiatry 71: 118-122, 2001
20. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859-863, 1998
21. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: The next step. J Clin Oncol 18: 3144-3150, 2000
22. Bessell EM, Graus F, Lopez-Guillermo A, Villa S, Verger E, Petit J, Holland I, Byrne P: CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 50: 457-464, 2001
23. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T: The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Blood 92: 3562-3568, 1998
24. Boiardi A, Silvani A, Pozzi A, Fariselli L, Broggi G, Salmaggi A: Chemotherapy is effective as early treatment for primary central nervous system lymphoma. J Neurol 246: 31-37, 1999
25. Ferreri AJ, Reni M, Dell'Oro S, Ciceri F, Bernardi M, Camba L, Ponzoni M, Terreni MR, Tomirotti M, Spina M, Villa E: Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 60: 134-140, 2001
26. Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML: Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neuro-Oncol 30: 257-265, 1996
27. Allen JC, Rosen G, Mehta BM, Horten B: Leukoencephalopathy following high-dose IV methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64: 1261-1273, 1980
28. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH: Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients. J Neuro-Oncol 43: 259-268, 1999
29. Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, DeSmet M, Kohler D, Simon R, Wittes R: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000-3006, 1998
30. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49: 2112-2135, 1982
31. Hryniuk WM, Bertino JR: Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J Clin Invest 48: 2140-2155, 1969
32. Reni M, Ferreri AJM, Garancini MP, Villa E: Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature. Ann Oncol 8: 227-234, 1997
33. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kuker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benohr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M, Weller M: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. 52: 247-252, 2002
34. Bessell EM, Lopez-Guillermo A, Villa S, Verger E, Nomdedeu B, Petit J, Byrne P, Montserrat E, Graus F: Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20: 231-236, 2002
35. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46: 51-60, 2000
36. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580-1590, 1991
37. Ferrari AJ, Reni M, Villa E: Primary nervous system lymphoma in immunocompetent patients. Cancer Treat Rev 21: 415-446, 1995
38. Ng S, Rosenthal MA, Ashley D, Cher L: High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro-Oncology 2: 40-44, 2000
39. Schlegel U, Pels H, Oehring R, Blümcke I: Neurologic sequelae of treatment of primary CNS lymphoma. J Neuro-Oncol 43: 277-286, 1999
40. Solberg TD, Selch MT, Smathers JB, DeSalles AAF: Fractionated stereotactic radiotherapy: Rationale and methods. Med Dosimetry 23: 209-219, 1998